Loading...
POLX logo

Polarean Imaging plcAIM:POLX Stock Report

Market Cap UK£965.6k
Share Price
n/a
1Y-93.8%
7D0%
1D-20.0%
Portfolio Value
View

Polarean Imaging plc

AIM:POLX Stock Report

Market Cap: UK£965.6k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Polarean Imaging (POLX) Stock Overview

Operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. More details

POLX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

POLX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Polarean Imaging plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Polarean Imaging
Historical stock prices
Current Share PriceUK£0.0008
52 Week HighUK£0.016
52 Week LowUK£0.0006
Beta0.28
1 Month Change0%
3 Month Change-84.00%
1 Year Change-93.85%
3 Year Change-99.86%
5 Year Change-99.88%
Change since IPO-99.50%

Recent News & Updates

Narrative Update Sep 26

Pharma Trials And Pediatric FDA Approval Will Open Global Markets

The consensus analyst price target for Polarean Imaging has been halved, reflecting downward revisions driven by declining profitability and a lower future P/E, resulting in a new fair value estimate of £0.04. What's in the News Polarean Imaging submitted a new Phase III clinical trial protocol to the FDA to expand XENOVIEW's indication to include quantitative gas-exchange imaging.

Recent updates

Narrative Update Sep 26

Pharma Trials And Pediatric FDA Approval Will Open Global Markets

The consensus analyst price target for Polarean Imaging has been halved, reflecting downward revisions driven by declining profitability and a lower future P/E, resulting in a new fair value estimate of £0.04. What's in the News Polarean Imaging submitted a new Phase III clinical trial protocol to the FDA to expand XENOVIEW's indication to include quantitative gas-exchange imaging.
User avatar
New Narrative May 11

Pharma Trials And Pediatric FDA Approval Will Open Global Markets

New revenue vertical in pharma-sponsored trials and FDA approval for younger patients expand market opportunities and potential revenue streams.
Analysis Article Feb 05

We're Not Very Worried About Polarean Imaging's (LON:POLX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Oct 16

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Jan 09

Here's Why Polarean Imaging (LON:POLX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Sep 11

Is Polarean Imaging (LON:POLX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Feb 09

Is Polarean Imaging (LON:POLX) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Oct 09

We're Keeping An Eye On Polarean Imaging's (LON:POLX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article Dec 15

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jul 07

We Think Shareholders Will Probably Be Generous With Polarean Imaging plc's (LON:POLX) CEO Compensation

We have been pretty impressed with the performance at Polarean Imaging plc ( LON:POLX ) recently and CEO Clairis...
Analysis Article Jun 07

Here's Why We're Watching Polarean Imaging's (LON:POLX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, Polarean...
Analysis Article Mar 18

Insider Buying: The Polarean Imaging plc (LON:POLX) Independent Chairman Just Bought 6.6% More Shares

Investors who take an interest in Polarean Imaging plc ( LON:POLX ) should definitely note that the Independent...
Analysis Article Mar 09

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Polarean Imaging...
Analysis Article Feb 01

Polarean Imaging (LON:POLX) Shareholders Have Enjoyed An Impressive 135% Share Price Gain

When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
Analysis Article Dec 28

Should You Take Comfort From Insider Transactions At Polarean Imaging plc (LON:POLX)?

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Analysis Article Nov 30

What Type Of Shareholders Own The Most Number of Polarean Imaging plc (LON:POLX) Shares?

The big shareholder groups in Polarean Imaging plc (LON:POLX) have power over the company. Institutions will often...

Shareholder Returns

POLXGB Medical EquipmentGB Market
7D0%1.1%-0.8%
1Y-93.8%-10.4%17.3%

Return vs Industry: POLX underperformed the UK Medical Equipment industry which returned 17.9% over the past year.

Return vs Market: POLX underperformed the UK Market which returned 20.7% over the past year.

Price Volatility

Is POLX's price volatile compared to industry and market?
POLX volatility
POLX Average Weekly Movement33.2%
Medical Equipment Industry Average Movement5.5%
Market Average Movement5.1%
10% most volatile stocks in GB Market10.4%
10% least volatile stocks in GB Market2.6%

Stable Share Price: POLX's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: POLX's weekly volatility has increased from 19% to 33% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201626Chris Von Jakopolarean.com

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest coil; Polarean 9820 Xenon hyperpolarizer that is designed to deliver up to 3 litres of hyperpolarized 129Xe per hour; and Polarean 2881 polarization measurement station, which provides a calibrated measurement of the polarization of hyperpolarized gas within the dose delivery inhalation bag.

Polarean Imaging plc Fundamentals Summary

How do Polarean Imaging's earnings and revenue compare to its market cap?
POLX fundamental statistics
Market capUK£965.63k
Earnings (TTM)-UK£7.11m
Revenue (TTM)UK£1.90m
0.5x
P/S Ratio
-0.1x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
POLX income statement (TTM)
RevenueUS$2.56m
Cost of RevenueUS$1.41m
Gross ProfitUS$1.16m
Other ExpensesUS$10.76m
Earnings-US$9.60m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.008
Gross Margin45.21%
Net Profit Margin-374.12%
Debt/Equity Ratio0%

How did POLX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 08:38
End of Day Share Price 2025/12/22 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Polarean Imaging plc is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colin SmithCapital Access Group